Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors

Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors

While gastrointestinal tumors remain a multifactorial and prevalent group of malignancies commonly treated surgically in combination with chemotherapy and radiotherapy, advancements regarding immunotherapeutic approaches continue to occur. Entering a new era of immunotherapy focused on overcoming re...

Full description

Bibliographic Details
Main Authors:	Paulina Chmiel, Katarzyna Gęca, Adam Michalski, Martyna Kłosińska, Agnieszka Kaczyńska, Wojciech P. Polkowski, Zuzanna Pelc, Magdalena Skórzewska
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	International Journal of Molecular Sciences
Subjects:	VISTA VSIR PD-1H Dies1 tumor microenvironment immunotherapy
Online Access:	https://www.mdpi.com/1422-0067/24/12/9945

Similar Items

Novel Approaches in Non-Melanoma Skin Cancers—A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC)
by: Paulina Chmiel, et al.
Published: (2022-10-01)

Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes
by: Kevin Yao, et al.
Published: (2023-03-01)

Investigation of HEG1, VISTA (VSIR) and PD-L1 expression levels in malignant mesothelioma by immunohistochemical methods and their relationship with histological subtypes
by: Medine Dicleli, et al.
Published: (2024-03-01)

Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade
by: Karsten A. Pilones, et al.
Published: (2020-01-01)

Identify the Prognostic and Immune Profile of VSIR in the Tumor Microenvironment: A Pan-Cancer Analysis
by: Yuanyuan Liu, et al.
Published: (2022-04-01)

VISTA, PDL-L1, and <i>BRAF</i>—A Review of New and Old Markers in the Prognosis of Melanoma
by: Andreea Cătălina Tinca, et al.
Published: (2022-01-01)

VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma
by: Aida Jlassi, et al.
Published: (2024-04-01)

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
by: Randolph J. Noelle, et al.
Published: (2023-09-01)

PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy
by: Quentin Wright, et al.
Published: (2021-07-01)

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
by: Shuxin Huang, et al.
Published: (2022-11-01)

VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy
by: Najibeh Shekari, et al.
Published: (2023-11-01)

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
by: Liru Wang, et al.
Published: (2018-09-01)

The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma
by: Nour el Imane Issam Salah, et al.
Published: (2023-08-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
by: Emily Hensler, et al.
Published: (2022-07-01)

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
by: Shawn Iadonato, et al.
Published: (2023-12-01)

Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes
by: Rafał Pęksa, et al.
Published: (2021-04-01)

Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
by: Shawn Iadonato, et al.
Published: (2024-01-01)

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma
by: Hai-Xia He, et al.
Published: (2021-01-01)

VISTA: A Promising Target for Cancer Immunotherapy?
by: Tagliamento M, et al.
Published: (2021-06-01)

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
by: Dia Roy, et al.
Published: (2023-10-01)

High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer
by: Ibtissam Rezouki, et al.
Published: (2023-04-01)

MDSD Multi-Plataforma: Más Allá de la Vista Funcional
by: Juan Camilo Jiménez, et al.
Published: (2016-05-01)

Tumor Budding Is an Independent Prognostic Factor in Pancreatic Adenocarcinoma and It Positively Correlates with PD-L1 Expression on Tumor Cells
by: Rafał Pęksa, et al.
Published: (2022-07-01)

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy
by: Xiaoshuang Niu, et al.
Published: (2023-11-01)

Novel immunotherapy in the management of advanced urothelial cancer - review of the literature
by: Paulina Chmiel, et al.
Published: (2022-08-01)

¡Hasta la vista, baby!: Un ensayo sobre los tecnopensamientos
by: Yolanda Contreras Bello
Published: (2011-07-01)

IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy
by: Xi-Yang Tang, et al.
Published: (2022-07-01)

Blockade of V‐domain immunoglobulin suppressor of T‐cell activation reprograms tumour‐associated macrophages and improves efficacy of PD‐1 inhibitor in gastric cancer
by: Yifan Cao, et al.
Published: (2024-02-01)

Preliminary analysis of immune-related markers in thymic carcinoid
by: Jiaqi Zhang, et al.
Published: (2023-12-01)

VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?
by: Markus Albertsmeier, et al.
Published: (2022-02-01)

Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy—A Systematic Review
by: Paulina Chmiel, et al.
Published: (2023-10-01)

Hart y el “sentido y propósito” del punto de vista interno
by: Natalia Scavuzzo
Published: (2021-09-01)

Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study
by: Juan Francisco Peña-Cardelles, et al.
Published: (2022-03-01)

VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
by: Xing Huang, et al.
Published: (2020-06-01)

LITERATURA, MEMÓRIA E HISTÓRIA: UM OLHAR TESTEMUNHAL PARA VISTA CHINESA
by: Luciana Iost Vinhas
Published: (2022-11-01)

Migrações E Múltiplas Identidades Dos Imigrantes Em Boa Vista - RR
by: Pedro Marcelo Staevie
Published: (2000-01-01)

Establishment of an Ex Vivo Tissue Culture Model for Evaluation of Antitumor Efficacy in Clear Cell Renal Cell Carcinoma
by: Shanjuan Hong, et al.
Published: (2022-04-01)

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
by: Rita Terenziani, et al.
Published: (2021-06-01)

Rodríguez-Blanco sobre el carácter inestable del punto de vista interno
by: Ezequiel Monti
Published: (2021-09-01)

Mapas, pontos de vista, perspectivas
by: Guido Boffi
Published: (2023-06-01)